Family · Pharmaceutical analytical standards
Irbesartan
A sartan for hypertension that blocks the AT1 receptor of angiotensin II: patented in 1990 and approved in 1997, it is also used to slow kidney damage in hypertensive patients with type 2 diabetes. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Unlike several other sartans it is not a prodrug: it is already active as it is, with no need to be converted by the body, and 60-80% of an oral dose is absorbed.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
